Your topics. New publications.

A compact browser notification when there’s something new. At most once a day — no account needed.

What interests you?

Optional and switchable off here at any time. We save your selected topics and device subscription; no email address is required. Privacy

Search the harborEN/DEAccount
Hallmarks of aging
Research brief

Frailty trajectories and new osteoporosis in adults aged 50 and over

In three large cohort studies of adults aged 50 and over, a higher baseline Frailty Index and its longitudinal trajectories were associated with new-onset osteoporosis. The abstract reports grip strength as a possible mediator and suggests monitoring frailty, but this is not evidence of cause. [1]

Automatic summary · not editorially reviewed

The key findings

  1. Frailty was measured with the Frailty Index, and frailty trajectories over time were identified. [1]

  2. Over median follow-up of 4, 6 and 8 years, 244, 2,693 and 1,986 participants developed osteoporosis. [1]

  3. The authors suggest that monitoring frailty and improving muscle strength may help reduce osteoporosis risk. [1]

The source at a glance

Study type / format
Longitudinal cohort study using data from three cohorts (abstract only).
Population / context
Adults aged 50 and over in the Health and Retirement Study, the English Longitudinal Study of Ageing and the Survey of Health, Ageing and Retirement in Europe.
Summary based on
Study abstract
Original publication
October 19, 2026

Baseline frailty and later osteoporosis in three cohorts

The question was whether frailty, measured with the Frailty Index (FI), predicts new osteoporosis. The researchers used data from adults aged 50 and over in three long-running studies: the Health and Retirement Study, the English Longitudinal Study of Ageing and the Survey of Health, Ageing and Retirement in Europe. Frailty was assessed with the FI, and the researchers identified frailty trajectories over time. They then examined links between baseline FI and these trajectories and incident osteoporosis, and explored nonlinear relationships and a possible mediating role of grip strength.

Supporting source [1]

Follow-up years and osteoporosis cases per cohort

Over median follow-up periods of 4, 6 and 8 years, 244 participants in the English cohort, 2,693 in the European survey cohort and 1,986 in the US cohort developed osteoporosis. The abstract does not report total sample sizes, how frailty trajectories were defined, or how grip strength was measured.

Supporting source [1]

Higher baseline FI linked to risk; causality not shown

Higher baseline FI was independently associated with greater osteoporosis risk in all cohorts; the abstract gives an adjusted hazard ratio of 1.43 (95% confidence interval 1.36–1.50) for one cohort. The authors conclude that baseline FI and its trajectories were significantly associated with osteoporosis and suggest that early identification and monitoring of frailty, and improving muscle strength, may help reduce risk. These are associations from observational cohorts, not proof that frailty causes osteoporosis or that strengthening muscles prevents it.

Supporting source [1]

How to interpret this

Abstract only; the full text was not reviewed. The abstract does not report total sample sizes, trajectory definitions, grip-strength measurement or adjustment details. Findings are observational associations, not causal effects, and the muscle-strength suggestion is not a tested intervention.

Based on the study abstract; the full paper, tables and supplementary data were not reviewed.

Source & supporting passages

Read the quoted passagesIn the language of the original source
  1. Finding 1 ↑

    We assessed frailty using the FI and
  2. Finding 2 ↑

    244, 2,693, and 1,986 participants in the
  3. Finding 3 ↑

    muscle strength improvement, may help reduce osteoporosis

AI-assisted summary with linked source passages. No independent editorial or clinical review.

Our editorial method

Discussion

Community discussions

0 topics

Member contributions. Share sources, disclose commercial interests, and avoid personal medical or dosing advice.

Loading…